

# Dissecting the Pathways and Enzymes Involved in the Maintenance of Cellular Lysophospholipid levels: Studies on Calcium-independent Phospholipase A<sub>2</sub>

Jesús Balsinde

*Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC),  
Universidad de Valladolid, 47003 Valladolid, Spain*

October 19, 2006

Arachidonic acid is an intermediate of a reacylation/deacylation cycle of membrane phospholipids in which the fatty acid is hydrolyzed from phospholipid by phospholipase A<sub>2</sub> and incorporated back by CoA-dependent acyltransferases. In resting cells, reacylation dominates; in stimulated cells the dominant reaction is deacylation. Enhanced arachidonate reacylation during cellular activation is still very significant, as reflected by the finding that the major part of the free fatty acid released by phospholipase A<sub>2</sub> is effectively re-incorporated into phospholipids.

Arachidonic acid incorporation into phospholipids depends on the availability of lysophospholipid acceptors, particularly lysophosphatidylcholine (lysoPC). In many cells, the levels of lysoPC appear to be maintained by the continuing action of the Ca<sup>2+</sup>-independent Group VIA phospholipase A<sub>2</sub> (iPLA<sub>2</sub>-VIA) on cellular phospholipids. Thus a decrease in the activity of iPLA<sub>2</sub>-VIA frequently results in the diminished production of lysoPC and hence in the inhibition of AA incorporation into phospholipids.

In resting conditions, iPLA<sub>2</sub>-VIA is thought to constitute the primary phospholipase involved in the liberation of fatty acids, including arachidonate, during the continuous recycling of membrane phospholipids that takes place under these conditions. Since, as indicated above, the rate of arachidonate release by iPLA<sub>2</sub>-VIA is lesser than the rate of its reacylation back into phospholipids, no net accumulation of free fatty acid occurs. Once arachidonic acid is initially incorporated into lysoPC by the action of CoA-dependent acyltransferases, it is transferred to certain lysophospholipids, particularly the ethanolamine lysophospholipids (lysoPE). Such a transfer is catalysed by the enzyme CoA-independent transacylase.

Within the framework of the model depicted in Fig. 1, recent studies have further explored the involvement of other phospholipases in addition to iPLA<sub>2</sub>-VIA in *housekeeping* phospholipid and fatty acid remodeling. Possible iPLA<sub>2</sub> roles in inflammatory signaling distinct from receptor-regulated arachidonate metabolism have also been investigated. These will be discussed later in this talk.

Our first objective [1] is to clarify the biochemical features of arachidonate incorporation into, and remodeling within, phospholipid species. Arachidonic acid incorporation into phospholipids was compared with the incorporation of eicosa-5,8,11,14,17-pentaenoic acid, an *n*-3 fatty acid.

In the second part [2], we discuss a model for fatty acid mobilization in H<sub>2</sub>O<sub>2</sub>-treated cells whereby the oxidant induces lipid oxidation, which results in accumulation of lipid peroxides at the membrane. These lipid peroxides destabilize the membrane and render it more susceptible to iPLA<sub>2</sub>-VIA attack, which

results in increased liberation of fatty acids. A mechanism like this may be relevant under pathophysiological conditions such as oxidative stress, where increased iPLA<sub>2</sub>-VIA activity may account for a significant phospholipid hydrolysis before cellular homeostasis is re-established.

The third part of the talk concerns with the inhibitor bromoenol lactone [3]. Originally described as a serine protease inhibitor, bromoenol lactone has been found to potently inhibit iPLA<sub>2</sub>-VIA. Thus, it has been frequently used to define biological roles of iPLA<sub>2</sub>-VIA in cells. However, bromoenol lactone is also known to inhibit another key enzyme of phospholipid metabolism, namely the magnesium-dependent phosphatidate phosphohydrolase-1. I will discuss the role of the latter enzyme in cell integrity and survival. Caution should be exercised when using bromoenol lactone in studies involving long incubation times, due to the capacity of this drug to induce iPLA<sub>2</sub>-VIA-independent apoptosis in a variety of cells.

To further expand our investigations on cellular functions of iPLA<sub>2</sub>-VIA, we prepared stably transfected cells overexpressing this enzyme [4]. Utilizing this strategy, we reassessed the role of iPLA<sub>2</sub>-VIA in oxidant-induced AA release and incorporation into phospholipids and extended our studies to the role of iPLA<sub>2</sub> in oxidant-induced apoptosis. These results indicate that, although iPLA<sub>2</sub>-VIA-mediated phospholipid hydrolysis occurs during apoptosis, iPLA<sub>2</sub>-VIA may actually be dispensable for the apoptotic process to occur. Thus, beyond a mere destructive role, the enzyme may play other roles during apoptosis.

In this regard [5], we have obtained data to suggest that formation of lysophosphatidylcholine by iPLA<sub>2</sub>-VIA in hydrogen peroxide-treated U937 cells to induce apoptosis directly contributes to their efficient clearance by macrophages. Thus, iPLA<sub>2</sub>-VIA-mediated membrane phospholipid hydrolysis in apoptotic cells plays a role in enabling macrophages to engulf the dying cells. iPLA<sub>2</sub>-VIA-induced lysoPC within the dying cell may function as a direct “eat me” signal that helps macrophages recognize and engulf the apoptotic cell.

An aspect that remains to be clarified is whether iPLA<sub>2</sub>-VIA, in addition to its housekeeping role in phagocytic cells in general, also plays some role in regulated phospholipid hydrolysis in phagocytic cells. The fact that multiple splice variants of iPLA<sub>2</sub> exist in some cells suggest the possibility that the enzyme may be subject to different regulatory mechanisms that differ among cell types. In this regard, we have obtained data that suggest that iPLA<sub>2</sub>-VIA may be capable of playing some signaling roles in cells aside from arachidonate metabolism [6]. Our data have identified iPLA<sub>2</sub>-VIA-mediated lysoPC production as a necessary component of the molecular machinery leading to lysozyme secretion in U937 cells and rule out a role for cytosolic group IVA phospholipase A<sub>2</sub> in the response, which in turn is responsible for all of the arachidonic acid mobilization. Collectively, the results demonstrate distinct roles in inflammatory cell signaling for two intracellular phospholipases.

In more recent results [7], we have noted that free arachidonic acid levels within the cells may provide an important cellular signal for the onset of apoptosis and that perturbations of the mechanisms controlling arachidonate reacylation, and hence free arachidonic acid availability, may decisively affect cell survival. The role of iPLA<sub>2</sub>-IVA in these events was studied in cells overexpressing the enzyme. These cells exhibit an increased basal hydrolysis of arachidonate-containing phospholipids, and hence of free arachidonic acid and, interestingly, also show augmented apoptosis rates when treated with hydrogen peroxide for extended periods of time.

***XXIV Meeting of the Spanish Society of Clinical Biochemistry, Wednesday, October 19-21, 2005, Valladolid, Spain (Metabolomics - Alternate Talk).***

**© The Eicosanoid Research Division. The U937 Cell Studies (2002–2006)**

Work supported by Grant BMC2001-2244 from the Spanish Ministry of Science and Technology, Grants BFU2004-01886/BMC and SAF2004-04676 from the Spanish Ministry of Education and Science, Grant CSI-4/02 from the Education Department of the Regional Government of Castile and León, and Grant 011232 from Fundació La Marató de TV3).

LIST OF SLIDES

1-----

Slide 1. PLA<sub>2</sub> regulation of AA release.

Slide 2. AA incorporation into and remodeling within phospholipids.

Slide 3. Effect of BEL on the incorporation of AA and EPA into the phospholipids of PMA-differentiated U937 cells.

Slide 4. Effect of different fatty acids on the incorporation of AA and EPA into phospholipids.

Slide 5. Effect of cellular activation by ConA on AA and EPA incorporation into phospholipids.

Slide 6. Concanavalin A-stimulated release of AA and EPA from PMA-differentiated U937 cells and effects of BEL and MAFP.

Slide 7. Distribution of AA or EPA among phospholipids.

Slide 8. Distribution of AA and EPA among phospholipid classes.

Slide 9. iPLA<sub>2</sub> activity of U937 cells.

2-----

Slide 10. H<sub>2</sub>O<sub>2</sub>-induced AA release from U937 cells.

Slide 11. Prostaglandin production by U937 cells exposed to H<sub>2</sub>O<sub>2</sub>.

Slide 12. Effect of MAFP and BEL on AA release from U937 cells.

Slide 13. Effect of pyrrophenone on AA release from U937 cells.

Slide 14. iPLA<sub>2</sub> antisense oligonucleotide inhibits iPLA<sub>2</sub> protein expression and activity and AA release in H<sub>2</sub>O<sub>2</sub>-treated U937 cells.

Slide 15. Effect of Ca<sup>2+</sup> on AA release from U937 cells.

Slide 16. Oleic acid release from U937 cells.

Slide 17. PLA<sub>2</sub> activity of homogenates from U937 cells.

Slide 18. Time course of PLA<sub>2</sub> activity using a natural membrane as substrate.

3-----

Slide 19. Cellular proliferation in the presence of BEL.

Slide 20. Effect of BEL on cell cycle distribution and nuclear morphology in U937 cells.

Slide 21. Staining of U937 cells with annexin-V.

Slide 22. Analysis of caspases in BEL-treated U937 cells.

Slide 23. Mitochondrial depolarization in BEL-treated U937 cells.

Slide 24. Annexin-V FITC labeling of different cell types after a BEL treatment.

Slide 25. Effect of iPLA<sub>2</sub> and PAP-1 inhibitors on annexin-V FITC staining of the U937 cells.

Slide 26. Inhibition of iPLA<sub>2</sub> in U937 cells.

Slide 27. Functional consequences of PAP-1 inhibition in U937 cells.

4-----

Slide 28. 1. Overexpression of iPLA<sub>2</sub> in U937 cells.

Slide 29. Effect of H<sub>2</sub>O<sub>2</sub> on AA release from iPLA<sub>2</sub>-overexpressing and control cells.

Slide 30. Effect of a cPLA<sub>2</sub> antisense oligonucleotide on stimulus-induced AA release.

Slide 31. Effect of thimerosal on H<sub>2</sub>O<sub>2</sub>-induced AA release.

Slide 32. Effect of H<sub>2</sub>O<sub>2</sub> on AA incorporation into U937 cell phospholipids.

Slide 33. Effect of H<sub>2</sub>O<sub>2</sub> on AA incorporation into phospholipids in iPLA<sub>2</sub>-overexpressing and control cells.

Slide 34. Effect of BEL on the incorporation of AA into phospholipids in iPLA<sub>2</sub>-overexpressing and control cells.

Slide 35. Annexin V-FITC labeling of iPLA<sub>2</sub>-overexpressing and control cells.

Slide 36. Changes in <sup>3</sup>H radioactivity in phospholipids and extracellular fatty acid release in [<sup>3</sup>H]AA-labeled U937 cells exposed to H<sub>2</sub>O<sub>2</sub>.

Slide 37. Role of iPLA<sub>2</sub> in H<sub>2</sub>O<sub>2</sub>-induced apoptosis.

5-----

Slide 38. Phagocytosis of apoptotic U937 cells by P388D<sub>1</sub> macrophages.

Slide 39. Effect of H<sub>2</sub>O<sub>2</sub> on nuclear morphology of U937 cells.

Slide 40. iPLA<sub>2</sub>-VIA modulates phagocytosis of apoptotic cells by macrophages.

Slide 41. LysoPC blocks phagocytosis of apoptotic cells by macrophages.

Slide 42. Antisense inhibition of cPLA<sub>2</sub>α does not affect U937 cell apoptosis or phagocytosis of the apoptotic cells by macrophages.

6-----

Slide 43. Lysozyme secretion from activated U937 cells.

Slide 44. The iPLA<sub>2</sub> antisense oligonucleotide inhibits lysozyme secretion in U937 cells.

Slide 45. iPLA<sub>2</sub> inhibition blocks lysozyme secretion by receptor agonists.

Slide 46. Effects of BEL and MAFP on PMA-induced AA release.

Slide 47. Effect of quercetin on AA release and lysozyme secretion in activated U937 cells.

Slide 48. LysoPC effects on lysozyme secretion in U937 cells.

7-----

Slide 49. Apoptosis of arachidonic acid depleted and non-depleted U937 cells.

Slide 50. AA incorporation and remodeling within phospholipids in U937 cells.

Slide 51. Effect of thimerosal on U937 cell apoptosis.

Slide 52. Effect of triacsin C on U937 cell apoptosis.

Slide 53. Effect of a CoA-IT inhibitor on U937 cell apoptosis.

Slide 54. Effect of cyclooxygenase or lipoxygenase inhibition on AA-induced U937 cell apoptosis.

## REFERENCES

1. Balsinde, J. 2002. Roles of various phospholipases A<sub>2</sub> in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. *Biochem. J.* 364: 695–702.
2. Balboa, M. A., and J. Balsinde. 2002. Involvement of calcium-independent phospholipase A<sub>2</sub> in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. *J. Biol. Chem.* 277: 40384–40389.
3. Fuentes, L., R. Pérez, M.L. Nieto, J. Balsinde, and M.A. Balboa. 2003. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A<sub>2</sub>. *J. Biol. Chem.* 278: 44683–44690.
4. Pérez, R., R. Melero, M.A. Balboa, and J. Balsinde. 2004. Role of group VIA calcium-independent phospholipase A<sub>2</sub> in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. *J. Biol. Chem.* 279: 40385–40391.
5. Pérez, R., M. A. Balboa, and J. Balsinde. 2006. Involvement of group VIA calcium-independent phospholipase A<sub>2</sub> in macrophage engulfment of hydrogen peroxide-treated U937 cells. *J. Immunol.* 176: 2555–2561.
6. Balboa, M. A., Y. Sáez, and J. Balsinde. 2003. Calcium-independent phospholipase A<sub>2</sub> is required for lysozyme secretion in U937 promonocytes. *J. Immunol.* 170: 5276–5280.
7. Pérez, R., X. Matabosch, A. Llebaria, M.A. Balboa, and J. Balsinde. 2006. Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. *J. Lipid Res.* 47: 484–491.
8. Balsinde, J., and M.A. Balboa. 2005. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A<sub>2</sub> in activated cells. *Cell. Signal.* 17: 1052–1062.
9. Balboa, M. A., and J. Balsinde. 2006. Oxidative stress and arachidonic acid mobilization. *Biochim. Biophys. Acta* 1761: 385–391.
10. Balsinde, J., R. Pérez, and M.A. Balboa. 2006. Calcium-independent phospholipase A<sub>2</sub> and apoptosis. *Biochim. Biophys. Acta* 1761: 1344–1350.
11. Winstead, M. V., J. Balsinde, and E. A. Dennis. 2000. Calcium-independent phospholipase A<sub>2</sub>: structure and function. *Biochim. Biophys. Acta* 1488: 28–39.
12. Balsinde, J., I.D. Bianco, E.J. Ackermann, K. Conde-Frieboes, and E.A. Dennis. 1995. Inhibition of calcium-independent phospholipase A<sub>2</sub> prevents arachidonic acid incorporation and phospholipid remodeling in P388D<sub>1</sub> macrophages. *Proc. Natl. Acad. Sci. U.S.A.* 92: 8527–8531.
13. Balsinde, J., M.A. Balboa, and E.A. Dennis. 1997. Antisense inhibition of group VI Ca<sub>2+</sub>-independent phospholipase A<sub>2</sub> blocks phospholipid fatty acid remodeling in murine P388D<sub>1</sub> macrophages. *J. Biol. Chem.* 272: 29317–29321.
14. Balsinde, J., and F. Mollinedo. 1988. Specific activation by concanavalin A of the superoxide anion generation

- capacity during U937 differentiation. *Biochem. Biophys. Res. Commun.* 151: 802–808.
15. Balsinde, J., and F. Mollinedo. 1990. Induction of the oxidative response and of concanavalin A-binding capacity in maturing human U937 cells. *Biochim. Biophys. Acta* 1052: 90–95.
  16. Balsinde, J., E. Diez, A. Schüller, and F. Mollinedo. 1988. Phospholipase A<sub>2</sub> activity in resting and activated human neutrophils. Substrate specificity, pH dependence, and subcellular localization. *J. Biol. Chem.* 263: 1929–1936.
  17. Fernández, B., J. A. Solís-Herruzo, and J. Balsinde. 1992. Mouse peritoneal macrophages contain an acylating system specific for twenty-carbon polyunsaturated fatty acids. A study with intact cells. *Eicosanoids* 5, 115–120.
  18. Balsinde, J., B. Fernández, J.A. Solís-Herruzo, and E. Diez. 1992. Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. *Biochim. Biophys. Acta* 1136: 75–82.
  19. Balsinde, J., B. Fernández, and J.A. Solís-Herruzo. 1994. Increased incorporation of arachidonic acid into phospholipids in zymosan-stimulated mouse peritoneal macrophages. *Eur. J. Biochem.* 221: 1013–1018.
  20. Balsinde, J., and E. A. Dennis. 1996. Distinct roles in signal transduction for each of the phospholipase A<sub>2</sub> enzymes present in P388D<sub>1</sub> macrophages. *J. Biol. Chem.* 271: 6758–6765.
  21. Balsinde, J., M.A. Balboa, and E.A. Dennis. 2000. Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D<sub>1</sub> macrophage-like cells. *J. Biol. Chem.* 275: 22544–22549.
  22. Balsinde, J., S.E. Barbour, I.D. Bianco, and E.A. Dennis. 1994. Arachidonic acid mobilization in P388D<sub>1</sub> macrophages is controlled by two distinct Ca<sup>2+</sup>-dependent phospholipase A<sub>2</sub> enzymes. *Proc. Natl. Acad. Sci. U. S. A.* 91: 11060–11064.
  23. Balsinde, J., M. A. Balboa, P. A. Insel, and E. A. Dennis. 1999. Regulation and inhibition of phospholipase A<sub>2</sub>. *Annu. Rev. Pharmacol. Toxicol.* 39: 175–89.
  24. Balboa, M. A., J. Balsinde, S. S. Jones, and E. A. Dennis. 1997. Identity between the Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> enzymes from P388D<sub>1</sub> macrophages and Chinese hamster ovary cells. *J. Biol. Chem.* 272: 8576–8580.
  25. Balsinde, J., M. V. Winstead, and E. A. Dennis. 2002. Phospholipase A<sub>2</sub> regulation of arachidonic acid mobilization. *FEBS Lett.* 531: 2–6.
  26. Fernández, B., and J. Balsinde. 1991. Receptor-mediated activation of arachidonic acid release in mouse peritoneal macrophages is linked to extracellular calcium influx. *Biochem. Biophys. Res. Commun.* 180: 1036–1040.
  27. Balsinde, J., M.A. Balboa, and E.A. Dennis. 1997. Inflammatory activation of arachidonic acid signaling in murine P388D<sub>1</sub> macrophages via sphingomyelin synthesis. *J. Biol. Chem.* 272: 20373–20377.
  28. Balsinde, J., and E. A. Dennis. 1996. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D<sub>1</sub> macrophages. *J. Biol. Chem.* 271: 31937–31941.
  29. Balboa, M. A., J. Balsinde, and E. A. Dennis. 1998. Involvement of phosphatidate phosphohydrolase in arachidonic acid mobilization in human amnionic WISH cells. *J. Biol. Chem.* 273: 7684–7690.
  30. Johnson, C. A., M. A. Balboa, J. Balsinde, and E. A. Dennis. 1999. Regulation of cyclooxygenase-2 expression by phosphatidate phosphohydrolase in human amnionic WISH cells. *J. Biol. Chem.* 274: 27689–27693.
  31. Balsinde, J., and E. A. Dennis. 1996. The incorporation of arachidonic acid into triacylglycerol in P388D<sub>1</sub> macrophage-like cells. *Eur. J. Biochem.* 235: 480–485.
  32. Balsinde, J., and E. A. Dennis. 1997. Function and inhibition of intracellular calcium-independent phospholipase A<sub>2</sub>. *J. Biol. Chem.* 272: 16069–16072.
  33. Balboa, M. A., R. Pérez, and J. Balsinde. 2003. Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A<sub>2</sub> is regulated by cytosolic phospholipase A<sub>2</sub>-derived hydroperoxyeicosatetraenoic acid. *J. Immunol.* 171: 989–994.
  34. Balsinde, J., M.A. Balboa, and E.A. Dennis. 1998. Functional coupling between secretory phospholipase A<sub>2</sub> and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A<sub>2</sub>. *Proc. Natl. Acad. Sci.*

U.S.A. 95: 7951–7956.

35. Balsinde, J., M. A. Balboa, S. Yedgar, and E. A. Dennis. 2000. Group V phospholipase A<sub>2</sub>-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D<sub>1</sub> macrophages. *J. Biol. Chem.* 275: 4783–4786.
36. Shirai, Y., J. Balsinde, and E. A. Dennis. 2005. Localization and functional interrelationships among cytosolic group IV, secreted group V, and Ca<sup>2+</sup>-independent group VI phospholipase A<sub>2</sub>s in P388D<sub>1</sub> macrophages using GFP/RFP constructs. *Biochim. Biophys. Acta* 1735: 119–129.
37. Balboa, M. A., Y. Shirai, G. Gaietta, M. H. Ellisman, J. Balsinde, and E. A. Dennis. 2003. Localization of group V phospholipase A<sub>2</sub> in caveolin-enriched granules in activated P388D<sub>1</sub> macrophage-like cells. *J. Biol. Chem.* 278: 48059–48065.
38. Balsinde, J., H. Shinohara, L. J. Lefkowitz, C. A. Johnson, M. A. Balboa, and E. A. Dennis. 1999. Group V phospholipase A<sub>2</sub>-dependent induction of cyclooxygenase-2 in macrophages. *J. Biol. Chem.* 274: 25967–25970.
39. Diez, E., J. Balsinde, M. Aracil, and A. Schüller. 1987. Ethanol induces release of arachidonic acid but not synthesis of eicosanoids in mouse peritoneal macrophages. *Biochim. Biophys. Acta* 921: 82–89.
40. Balsinde, J., B. Fernández, and E. Diez. 1990. Regulation of arachidonic acid release in mouse peritoneal macrophages. The role of extracellular calcium and protein kinase C. *J. Immunol.* 144: 4298–4304.
41. Balsinde, J., B. Fernández, J.A. Solís-Herruzo, and E. Diez. 1992. Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. *Biochim. Biophys. Acta* 1136: 75–82.